In-silico clinical trials market to hit $6.39b by 2033

Drug development represented the largest market share.

The in-silico clinical trials market is expected to reach $6.39b by 2033 at a compound annual growth rate of 5.5%, according to a DataM Intelligence report.

IST platforms are increasingly used to address rising drug development costs, delayed approvals, protocol failures, and patient-recruitment challenges.

“These computational simulations enable researchers to digitally model drug candidates, medical devices, dosing strategies, toxicity profiles, and responses across diverse patient subpopulations,” the report said.

Drug development represented the largest share of the market, accounting for nearly 52% of global revenue in 2024.